TRIAL DETAIL

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Drug:
Trial Name:
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 07/01/2011
Age of Trial (yrs) 10.4
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K/mTOR inhibitor + MEK inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CMEK162X2103, EudraCT 2011-000421-74
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals 800-340-6843
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results

Drug Information

Combined inhibition of MAP kinase and KIT signaling effectively destabilizes the ETV1 protein and synergistically suppresses GIST tumorigenesis
 

Trial Sites

Name
Address
City
State
Zip
Country
1505 Holcombe Blvd.
Houston
TX
77030
USA
610 University Ave
Toronto
ON
M5G 2M9
Canada
Villejuif
Val de Narne
94805
France
Grattan Street
Parkville
Victoria
3050
Australia
119-129
Barcelona
08035
Spain
Hufelandstr. 55
Essen
45122
Germany
Cologne
D-50924
Germany
Madison
WI
53792
USA
55 Fruit Street
Boston
MA
02114
USA